Screener / SEC EDGAR /CIK 0001906324 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Diagnostics

QuidelOrtho Corp QDEL

Compare with peers Embed
New in the 10-K 10 paragraphs with nothing like them in the 10-K filed Feb 27, 2025 New in the 10-Q 30 paragraphs not in the 10-Q filed Aug 7, 2026 10-Q against the 10-K 0 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 27, 2025. A box jumps to the paragraph as filed, below.

10 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

10 paragraphs in Risk Factors of the 10-K filed Feb 19, 2026 with nothing like them in the 10-K filed Feb 27, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

•our inability to generate cash flow sufficient to service our debt obligations;

Read in the 10-K

Our collaboration arrangements may not operate according to our business strategy and if we are unable to maintain our collaboration arrangements, or if these collaboration arrangements are not successful, our results of operations could be materially adversely affected.

Read in the 10-K

We may engage in strategic transactions, including acquisitions, investments, joint ventures, licensing arrangements and other strategic relationships, undertake strategic restructurings or divest, spin-off or discontinue certain business operations, and may not successfully identify or consummate these strategic transactions; therefore, we may not realize the anticipated benefits of these transactions, if any.

Read in the 10-K

We may also undertake initiatives to restructure or streamline our operations in order to achieve cost savings and improve operational efficiency. For example, in the second quarter of 2025, we launched the Optimization Plan that aims to (i) realign our costs with our long-term revenue expectations, (ii) drive operational efficiencies in manufacturing and distribution cost bases and (iii) support and align with our strategy to invest in key priorities. The cumulative pre-tax charges to be incurred by us to implement the Optimization Plan are expected to be approximately $100 million through 2027, and the Optimization Plan is expected to deliver net cost savings of approximately $50 million to be achieved through 2027. However, the timing, magnitude and nature of costs associated with implementing a restructuring initiative and the resulting cost savings are uncertain. We may incur costs beyond the amount contemplated when we first developed the initiative, and these increased costs may be substantial, which could adversely impact our results of operations for the periods in which those adjustments are made. Additionally, there can be no assurance we will realize the intended benefits of a strategic restructuring on the expected timeline, or at all. Failure to successfully execute the Optimization Plan or any other strategic restructuring on a timely basis, or the failure to realize the expected benefits of such strategic restructuring or mitigate associated risks and disruptions, may have a material adverse effect on our business, financial condition and results of operations.

Read in the 10-K

incur increased costs from insurance premiums and remediation measures and subject us to potential liability, litigation and regulatory or other government action. If any of the foregoing were to occur, our business strategy, results of operations or financial condition could be materially and adversely affected.

Read in the 10-K
Show the other 4

Outside the U.S., commercialization is subject to diverse and evolving regulatory regimes, including, for example, the EU IVDR, Health Canada licensing and the NMPA in China. These regulatory regimes may require local clinical evidence, language- and country-specific labeling, post-market surveillance and vigilance reporting, and periodic renewals or new registrations for variations. Timelines, standards of review, and enforcement approaches differ by jurisdiction and are subject to change; authorities may suspend, revoke or impose conditions on existing authorizations, require product modifications or prohibit marketing.

Read in the 10-K

criminal and civil penalties, termination of contracts and suspension or debarment from government contract work. These requirements complicate our business and increase our compliance burden. The failure to meet key deliverables, milestones or compliance requirements could harm our reputation and may have a materially adverse impact on our business operations and our financial position or results of operations.

Read in the 10-K

we had total indebtedness of $2.65 billion, and we had availability under our Revolving Credit Facility of $596.6 million (net of $23.4 million of outstanding letters of credit and $80.0 million borrowings outstanding).

Read in the 10-K

If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our common stock.

Effective internal controls are necessary for us to provide reliable financial reports, prevent fraud and operate successfully as a public company. If we cannot provide reliable financial reports or prevent fraud, our reputation and operating results would be harmed. We cannot be certain that our efforts to develop and maintain an effective system of internal controls will be successful, that we will be able to maintain adequate controls over our financial processes and reporting in the future, or that we will be able to comply with our obligations under Section 404 of the Sarbanes-Oxley Act of 2002. Any failure to develop or maintain effective internal controls, or difficulties encountered in implementing or improving internal controls, could harm our operating results or cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which would likely have a negative effect on the trading price of our common stock.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before

New in the latest 10-Q

30 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 7, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

Reclassification of net realized losses (gains) on derivative instruments included in net income 1.1 (2.9) 3.3 (10.2)

Read in the 10-Q

Total change in unrealized gains (losses) from cash flow hedges, net of tax 56.5 (12.0) 85.7 (41.8)

Read in the 10-Q

Certain reclassifications have been made to prior period amounts to conform to the current period presentation.

Read in the 10-Q

(4) Represents reserves accrued in connection with the resolution of a contractual dispute. Refer to “ - Note 11. Commitments and Contingencies” for additional information.

Read in the 10-Q

During the third quarter of 2025, the Company concluded that the sustained decline in the Company’s stock price and market capitalization was a triggering event requiring an interim goodwill impairment assessment for all reporting units.

Read in the 10-Q
Show the other 25

Based on the Company’s interim goodwill impairment assessment in the third quarter of 2025, the Company recorded a non-cash goodwill impairment charge of $ 700.7 million, which represented a full impairment of goodwill. As of September 28, 2025, no goodwill remained on the Company’s Consolidated Balance Sheets.

Read in the 10-Q

On September 23, 2026, the Company entered into Amendment No. 1 (the “Amendment”) to its existing credit agreement, dated as of August 21, 2025 (as amended by the Amendment, the “Credit Agreement”), by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender (“Bank of America”), and the other lenders and L/C issuers party thereto (together with Bank of America, the “Lenders”). Pursuant to the Credit Agreement, the Lenders provided the Company with (i) a $ 1.15 billion senior secured term loan A facility (the “Term Loan A”), (ii) a $ 100.0 million senior secured delayed draw term loan A facility (the “DDTL Term Loan A”; together with the Term Loan A, the “Term Loan A Facilities”), (iii) a $ 1.45 billion senior secured term loan B facility (the “Term Loan B”) and (iv) a $ 700.0 million revolving credit facility (the “Revolving Credit Facility” and collectively with the Term Loan A, the DDTL Term Loan A and the Term Loan B, the “Financing”). The Financing remains guaranteed by certain material domestic subsidiaries of the Company (the “Guarantors”) and secured by liens on substantially all of the assets of the Company and the Guarantors, excluding real property and certain other types of excluded assets. The Amendment, among other matters, reset the Company’s financial covenant levels through the fiscal quarter ending September 30, 2029 (such period, the “Covenant Relief Period”), to provide for a maximum Consolidated Leverage Ratio (as defined in the Credit Agreement) for each measurement period as follows: (a) 5.50 to 1.00 on or prior to July 2, 2028, (b) 5.00 to 1.00 on October 1, 2028 or December 31, 2028, (c) 4.50 to 1.00 on April 1, 2029 or July 1, 2029, and (d) 4.25 to 1.00 on or after September 30, 2029. The Amendment also reset the minimum Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) during the Covenant Relief Period for each measurement period as follows: (a) 2.25 to 1.00 on or prior to July 2, 2028, (b) 2.50 to 1.00 on October 1, 2028 or December 31, 2028, (c) 2.75 to 1.00 on April 1, 2029 or July 1, 2029, and (d) 3.00 to 1.00 on or after September 30, 2029. During the Covenant Relief Period, the initial applicable rate for the Term Loan A Facilities and the Revolving Credit Facility from the Amendment effective date until the first business day after Bank of America’s receipt of the compliance certificate for the fiscal quarter ended September 27, 2026 is 1.50 % per annum for base rate loans and 2.50 % per annum for Term SOFR rate loans, and thereafter will be determined in accordance with a pricing grid based on the Company’s Consolidated Leverage Ratio ranging

Read in the 10-Q

from 1.75 % to 3.00 % per annum for Term SOFR rate loans and from 0.75 % to 2.00 % per annum for base rate loans. In addition, during the Covenant Relief Period, the Company will pay a commitment fee on the unused portion of the Credit Agreement based on the Company’s Consolidated Leverage Ratio ranging from 0.20 % to 0.40 % per annum. The interest payable on the Term Loan B remains unchanged by the Amendment.

Read in the 10-Q

The Amendment was accounted for as a debt modification. The Company incurred and paid $ 4.3 million of Lender fees, consisting of $ 2.7 million related to Term Loan A and $ 1.6 million related to the Revolving Credit Facility. Lender fees related to Term Loan A were recorded as a reduction of the principal amount of the borrowings and are amortized using the effective interest method as a component of Interest expense, net over the remaining life of the Term Loan A. Lender fees related to the Revolving Credit Facility were recorded as Other assets and are amortized on a straight-line basis over the term of the Revolving Credit Facility. Additionally, the Company incurred $ 0.5 million of third-party costs, which were expensed as Selling, marketing and administrative expenses in the Consolidated Statements of Loss.

Read in the 10-Q

During the third quarter of 2025, a final judgment was entered relating to a dispute with a potential supplier for COVID-19 pandemic raw materials and services, which required the Company to pay monetary damages of $ 10.8 million, which was paid in the fourth quarter of 2025. Consistent with ASC 450, for the three months ended April 2, 2023, the Company accrued reserves of $ 1.4 million for this matter, representing the minimum amount in the then-estimable range of loss. The Company accrued additional reserves of $ 9.4 million for this matter in the third quarter of 2025.

Read in the 10-Q

In the fourth quarter of 2026, we launched a new cost transformation and enterprise restructuring program designed to further improve our cost structure and evolve our operating model around two focused businesses, Core Diagnostics and Point of Care Diagnostics. The new operating model is designed to increase customer focus, create clearer accountability for business performance, and better align technology development and investment priorities with the distinct needs of each business. We expect the program to deliver over $80 million in annual savings in 2027 and to record approximately $30 to $35 million in one-time restructuring charges in the fourth quarter of 2026.

Read in the 10-Q

Our respiratory products revenue may be impacted by customer purchasing patterns for the 2026-2027 respiratory season, which are influenced by respiratory disease trends, customer demand expectations, and inventory levels. Further, our SOFIA 2 Flu + SARS Antigen FIA (“SOFIA Combo”) test is authorized by the U.S. Food and Drug Administration ("FDA") under an emergency use authorization ("EUA") related to COVID-19. The U.S. Department of Health and Human Services ("HHS") has announced that the declaration supporting EUAs for COVID-19 IVD tests will terminate effective December 26, 2026, and we have been actively managing this transition with our customers. Under applicable FDA and U.S. Centers for Medicare & Medicaid Services ("CMS") transition guidance, SOFIA Combo tests that we distribute prior to the termination date may continue to be sold by our distributor customers and used by health care providers through their labeled expiration dates under the same circumstances in a manner consistent with the EUA in effect prior to the termination date. In addition, we may continue to sell and distribute SOFIA Combo tests after the termination date if we submit a 510(k) marketing submission that is accepted by the FDA before the termination date and we otherwise comply with the transition policies of FDA and CMS. In the near term, some customers may purchase greater quantities of SOFIA Combo tests in advance of the termination date, which could affect the timing of respiratory products revenue, and future sales of SOFIA Combo tests will depend on the status of any applicable 510(k) marketing submission. As a result, the EUA termination may contribute to variability in our respiratory products revenue.

Read in the 10-Q

Outside of China, our Labs and Immunohematology business units, which represent a majority of our Total revenues, continued to experience steady demand during the first nine months of 2026, which we believe was supported by our long-term customer relationships and installed base in key markets.

Read in the 10-Q

We recognized an impairment charge of $12.5 million as a result of the latest fair value assessment for the three and nine months ended September 27, 2026, and $9.7 million for the three and nine months ended September 28, 2025, related to the Raritan, NJ facility, which continues to meet the criteria to be classified as assets held for sale.

Read in the 10-Q

On September 23, 2026, we entered into the Amendment to our existing credit agreement. Pursuant to the Credit Agreement, the Lenders provided us with (i) a $1.15 billion Term Loan A, (ii) a $100.0 million DDTL Term Loan A, (iii) a $1.45 billion Term Loan B and (iv) a $700.0 million Revolving Credit Facility. The Financing remains guaranteed by the Guarantors and secured by liens on substantially all of our and the Guarantors’ assets, excluding real property and certain other types of excluded assets. The Amendment, among other matters, reset our financial covenant levels during the Covenant Relief Period to provide for a maximum Consolidated Leverage Ratio for each measurement period as follows: (a) 5.50 to 1.00 on or prior to July 2, 2028, (b) 5.00 to 1.00 on October 1, 2028 or December 31, 2028, (c) 4.50 to 1.00 on April 1, 2029 or July 1, 2029, and (d) 4.25 to 1.00 on or after September 30, 2029. The Amendment also reset the minimum Consolidated Interest Coverage Ratio during the Covenant Relief Period for each measurement period as follows: (a) 2.25 to 1.00 on or prior to July 2, 2028, (b) 2.50

Read in the 10-Q

to 1.00 on October 1, 2028 or December 31, 2028, (c) 2.75 to 1.00 on April 1, 2029 or July 1, 2029, and (d) 3.00 to 1.00 on or after September 30, 2029. During the Covenant Relief Period, the initial applicable rate for the Term Loan A Facilities and the Revolving Credit Facility from the Amendment effective date until the first business day after Bank of America’s receipt of the compliance certificate for the fiscal quarter ended September 27, 2026 is 1.50% per annum for base rate loans and 2.50% per annum for Term SOFR rate loans, and thereafter will be determined in accordance with a pricing grid based on our Consolidated Leverage Ratio ranging from 1.75% to 3.00% per annum for Term SOFR rate loans and from 0.75% to 2.00% per annum for base rate loans. In addition, during the Covenant Relief Period, we will pay a commitment fee on the unused portion of the Credit Agreement based on our Consolidated Leverage Ratio ranging from 0.20% to 0.40% per annum. The interest payable on the Term Loan B remains unchanged by the Amendment.

Read in the 10-Q

The Amendment was accounted for as a debt modification. We incurred and paid $4.3 million of Lender fees, consisting of $2.7 million related to Term Loan A and $1.6 million related to the Revolving Credit Facility. Lender fees related to Term Loan A were recorded as a reduction of the principal amount of the borrowings and are amortized using the effective interest method as a component of Interest expense, net over the remaining life of the Term Loan A. Lender fees related to the Revolving Credit Facility were recorded as Other assets and are amortized on a straight-line basis over the term of the Revolving Credit Facility. Additionally, we incurred $0.5 million of third-party costs, which were expensed as Selling, marketing and administrative expenses in the Consolidated Statements of Loss.

Read in the 10-Q

Availability under the Revolving Credit Facility, after deducting letters of credit of $18.0 million and $315.0 million borrowings outstanding, was $367.0 million as of September 27, 2026.

Read in the 10-Q

Item 6

3.1 Amended and Restated Certificate of Incorporation of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on May 27, 2022)

Read in the 10-Q

3.2 Amended and Restated Bylaws of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K filed on December 13, 2022)

Read in the 10-Q

3.3 Certificate of Change of Registered Agent (incorporated by reference to Exhibit 3.3 to the Registrant’s Form 10-K filed on February 23, 2023)

Read in the 10-Q

4.1 Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Form 10-Q filed on August 5, 2022)

Read in the 10-Q

10.1 Amendment No. 1, dated as of September 23, 2026, by and among QuidelOrtho Corporation, as borrower, the Guarantors, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and L/C issuers party thereto (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on September 23, 2026)

Read in the 10-Q

10.2(1) QuidelOrtho Corporation 2026 Inducement Plan (incorporated by reference to Exhibit 99.1 to the Registrant’s Form S-8 filed on July 13, 2026)

Read in the 10-Q

10.3(1) QuidelOrtho Corporation 2026 Inducement Plan Nonqualified Stock Option Award Agreement (incorporated by reference to Exhibit 10.2 to the Registrant’s Form 10-Q filed on August 7. 2026)

Read in the 10-Q

10.4(1) QuidelOrtho Corporation 2026 Inducement Plan Restricted Stock Unit Award Terms and Conditions (incorporated by reference to Exhibit 10.3 to the Registrant’s Form 10-Q filed on August 7. 2026)

Read in the 10-Q

31.1* Certification by Principal Executive Officer of QuidelOrtho Corporation pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Read in the 10-Q

31.2* Certification by Principal Financial Officer of QuidelOrtho Corporation pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Read in the 10-Q

32.1** Certifications by Principal Executive Officer and Principal Financial Officer of QuidelOrtho Corporation pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Read in the 10-Q

101 The following financial statements, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Loss, (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 19, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:There has been no material change in our risk factors as previously disclosed in our Annual Report. For a detailed description of our risk factors, refer to Part I, Item 1A, “Risk Factors” of our Annual Report.

Read in the 10-Q

1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 19, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 27, 2025

collaboration partners ×6strategic transactions ×5third-party collaboration ×5strategic relationships ×4optimization plan ×4staffing constraints ×3successfully identify ×3legal proceedings ×3contracting process ×3strategic restructuring ×3prevent fraud ×3strategic restructurings ×2customs valuation ×2classification requirements ×2product systems ×2penalties risks ×2
Where each one is used
  • collaboration partners: •our inability, or that of our providers or third-party collaboration partners, to protect our information systems in our IT and product systems, and personal and confidential information, including from data corruption, cyber-attacks, security breaches or IT errors;
  • strategic transactions: •inability to successfully identify or consummate strategic transactions, strategic restructurings or divestitures, spin-offs or discontinuances of certain business operations, or to realize the anticipated benefits;
  • third-party collaboration: •our inability, or that of our providers or third-party collaboration partners, to protect our information systems in our IT and product systems, and personal and confidential information, including from data corruption, cyber-attacks, security breaches or IT errors;
  • strategic relationships: We may engage in strategic transactions, including acquisitions, investments, joint ventures, licensing arrangements and other strategic relationships, undertake strategic restructurings or divest, spin-off or discontinue certain business operations, and may not successfully identify or consummate these strategic...
  • optimization plan: We may also undertake initiatives to restructure or streamline our operations in order to achieve cost savings and improve operational efficiency. For example, in the second quarter of 2025, we launched the Optimization Plan that aims to (i) realign our costs with our long-term revenue expectations, (ii) drive...
  • staffing constraints: •significant changes in the healthcare industry and related industries that we serve, including staffing constraints and efforts to reduce costs;
  • successfully identify: •inability to successfully identify or consummate strategic transactions, strategic restructurings or divestitures, spin-offs or discontinuances of certain business operations, or to realize the anticipated benefits;
  • legal proceedings: As part of our business, we are party to collaboration arrangements with other companies and we may enter into additional collaboration arrangements in the future. The nature of a collaboration arrangement requires us to share control over significant decisions with unaffiliated third parties. Since we do not...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

24 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
Effective internal controls are necessary for us to provide reliable and accurate financial reporting and financial statements for external purposes in accordance with GAAP. A failure to maintain effective internal control over financial reporting could lead to violations, unintentional or otherwise, of laws and regulations. As disclosed in Part II, Item 9A, “Controls and Procedures” of this Annual Report, as of December 29, 2024, we identified material weaknesses in our internal control over financial reporting relating to (i) ineffectively designed controls related to financial...
In the 10-K filed Feb 27, 2025
Many of these factors are outside of our control and any one of them could subject us to increased costs, decreased revenues and diversion of management’s and employees’ time and energy, which could materially impact our business, financial condition and results of operations. In addition, we are transitioning from integration efforts of the two independent businesses to focusing on business efficiencies of the combined company with the goal of creating a more efficient and agile company. We may not realize the full benefits of the Combinations and our business efficiency initiatives,...
In the 10-K filed Feb 27, 2025
As a result of the Combinations, we have been and continue to devote significant management and employee attention and resources to integrate the business practices and operations of Quidel and Ortho. The integration process may disrupt our business and, if implemented ineffectively, could preclude realization of the full benefits we expect to result from the Combinations. Any failure to meet the challenges involved in successfully integrating the operations of Quidel and Ortho or otherwise to realize the anticipated benefits of the Combinations could also seriously harm our results of...
In the 10-K filed Feb 27, 2025
We have incurred and expect to continue to incur a number of non-recurring direct and indirect costs associated with the Combinations. There are processes, policies, procedures, operations, technologies and systems that still must be integrated in connection with the Combinations and the integration of Quidel’s and Ortho’s businesses. While we have assumed that a certain level of expenses would be incurred in connection with the Combinations and continue to assess the magnitude of these costs, there are many factors beyond our control that could affect the total amount or the timing of the...
In the 10-K filed Feb 27, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/QDEL/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.